Stock Analysis, Dividends, Split History

FENC / Fennec Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.44
Volume74,800.00
Market Cap ($M)185.14
Enterprise Value ($M)158.42
Book Value ($M)24.86
Book Value / Share1.31
Price / Book7.21
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 18,411,000
Common Shares Outstanding 18,464,706
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.26
Return on Assets (ROA)-1.77
Return on Equity (ROE)-1.97
Balance Sheet (mrq) ($M)
Assets25.70
Liabilities0.85
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenue From Grants0.00
Revenues0.00
Operating Income-6.95
Net Income-7.05
Earnings Per Share Basic-0.47
Earnings Per Share Diluted-0.47
Earnings Per Share Basic And Diluted-0.47
Cash Flow Statement (mra) ($M)
Cash From Operations-3.64
Cash from Investing0.00
Cash from Financing0.00
Identifiers and Descriptors
CUSIP00686R200
Central Index Key (CIK)1211583

Split History

Stock splits are used by Fennec Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Fennec Pharma: Assured Patience To Be Greatly Rewarded

2018-07-17 seekingalpha
Lack of known near-term catalysts and dwindling cash have attracted shorts to shares of Fennec Pharma. (0-2)

Synergy Pharmaceuticals: Better Days Likely Ahead, But Better Opportunities Elsewhere

2018-06-13 seekingalpha
We look back at the flawed investment thesis we presented late last year and learn from our mistakes. (359-1)

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)

Fennec's stock soars further after PEDMARK receives 'breakthrough therapy' designation - MarketWatch

2018-03-27 marketwatch
Shares of Fennec Pharmaceuticals Inc. FENC, -0.37% were indicated up over 12% in premarket trade Tuesday, after the specialty pharmaceutical company said its PEDMARK to prevent cisplatin ototoxicity in pediatric patients with liver cancer was granted a "breakthrough therapy" designation by the Food and Drug Administration. Breakthrough therapy designation is given when there is preliminary clinical evidence that a treatment represents substantial improvement over available therapies, and includes fast-track program features. (2-0)

Top Analyst Upgrades and Downgrades: Apollo, ADM, Cigna, HubSpot, Intuit, Newmont, Nike, SAP, Time Warner and More

2018-03-12 247wallst
Stocks were up big on Friday after a solid jobs report and less wage inflation. The major stock market indexes were indicated to open marginally higher on Monday as well. The bull market is now more than nine years old, and the one trend that has prevailed for more than five years has been for investors to buy all the big pullbacks. Investors also still have to decide how they want to be positioned for the rest of 2018 and beyond. (187-4)

Silicon Investor Message Boards

This table lists all message boards related to FENC / Fennec Pharmaceuticals Inc. on message board site Silicon Investor.

Shareholder Abuse and Defences against Shareholder Abuse and Defences against Shareholder Abuse and Defences against
CUSIP: 00686R200